Shares of Mesoblast Limited (MESO) touched a new 52-week high of $12.70 yesterday, as the company awaits the FDA decision on Ryoncil in the proposed indication of pediatric steroid-refractory acute graft versus host disease.
Ryoncil, also known as Remestemcel-L, comprises of culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com